SE9200541D0 - New usee of omega-3-fatty acids - Google Patents

New usee of omega-3-fatty acids

Info

Publication number
SE9200541D0
SE9200541D0 SE9200541A SE9200541A SE9200541D0 SE 9200541 D0 SE9200541 D0 SE 9200541D0 SE 9200541 A SE9200541 A SE 9200541A SE 9200541 A SE9200541 A SE 9200541A SE 9200541 D0 SE9200541 D0 SE 9200541D0
Authority
SE
Sweden
Prior art keywords
omega
pct
preparations
fatty acids
dic
Prior art date
Application number
SE9200541A
Other languages
English (en)
Swedish (sv)
Inventor
N Engberg
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9200541A priority Critical patent/SE9200541D0/xx
Publication of SE9200541D0 publication Critical patent/SE9200541D0/xx
Priority to SG1996001422A priority patent/SG46238A1/en
Priority to PCT/SE1993/000146 priority patent/WO1993016691A1/en
Priority to EP93905710A priority patent/EP0627918B1/en
Priority to DK93905710T priority patent/DK0627918T3/da
Priority to AU36529/93A priority patent/AU671438B2/en
Priority to ES93905710T priority patent/ES2162620T3/es
Priority to JP51475493A priority patent/JP3559280B2/ja
Priority to CA002117535A priority patent/CA2117535A1/en
Priority to US08/290,905 priority patent/US5747533A/en
Priority to AT93905710T priority patent/ATE207744T1/de
Priority to DE69331051T priority patent/DE69331051T2/de
Priority to NO943102A priority patent/NO309704B1/no
Priority to US08/483,977 priority patent/US5731346A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9200541A 1992-02-24 1992-02-24 New usee of omega-3-fatty acids SE9200541D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids
DE69331051T DE69331051T2 (de) 1992-02-24 1993-02-23 Neue verwendung von omega-3-fettsäuren
ES93905710T ES2162620T3 (es) 1992-02-24 1993-02-23 Nuevo uso de los acidos grasos omega 3.
PCT/SE1993/000146 WO1993016691A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids
EP93905710A EP0627918B1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids
DK93905710T DK0627918T3 (da) 1992-02-24 1993-02-23 Ny anvendelse af omega-3-fedtsyrer
AU36529/93A AU671438B2 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids
SG1996001422A SG46238A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids
JP51475493A JP3559280B2 (ja) 1992-02-24 1993-02-23 オメガ−３−脂肪酸の用法
CA002117535A CA2117535A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids
US08/290,905 US5747533A (en) 1992-02-24 1993-02-23 Use of ω-3-fatty acids
AT93905710T ATE207744T1 (de) 1992-02-24 1993-02-23 Neue verwendung von omega-3-fettsäuren
NO943102A NO309704B1 (no) 1992-02-24 1994-08-23 Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC)
US08/483,977 US5731346A (en) 1992-02-24 1995-06-07 Use of omega-3-fatty acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids

Publications (1)

Publication Number Publication Date
SE9200541D0 true SE9200541D0 (sv) 1992-02-24

Family

ID=20385410

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids

Country Status (13)

Country Link
US (2) US5747533A (xx)
EP (1) EP0627918B1 (xx)
JP (1) JP3559280B2 (xx)
AT (1) ATE207744T1 (xx)
AU (1) AU671438B2 (xx)
CA (1) CA2117535A1 (xx)
DE (1) DE69331051T2 (xx)
DK (1) DK0627918T3 (xx)
ES (1) ES2162620T3 (xx)
NO (1) NO309704B1 (xx)
SE (1) SE9200541D0 (xx)
SG (1) SG46238A1 (xx)
WO (1) WO1993016691A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
WO1998057628A1 (fr) * 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
US6054481A (en) * 1998-01-21 2000-04-25 Fideline Pig appeasing pheromones for enhancing weight gain in a mammal
US6077867A (en) 1998-01-21 2000-06-20 Fideline Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
JP4754688B2 (ja) * 1998-01-21 2011-08-24 フィドゥラン ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
FR2804023B1 (fr) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr Complement nutritionnel a base d'huile de pepins de cassis
WO2002069964A1 (en) * 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20060088596A1 (en) 2004-09-28 2006-04-27 Atrium Medical Corporation Solubilizing a drug for use in a coating
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
AU2006273696B2 (en) * 2005-06-24 2012-08-30 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
CA2692394A1 (en) * 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) * 2007-11-30 2010-12-23 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
AU596880B2 (en) * 1986-09-17 1990-05-17 Clintec Nutrition Company Liquid nutritional compositions
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Also Published As

Publication number Publication date
AU671438B2 (en) 1996-08-29
CA2117535A1 (en) 1993-09-02
ATE207744T1 (de) 2001-11-15
SG46238A1 (en) 1998-02-20
JPH07507766A (ja) 1995-08-31
NO309704B1 (no) 2001-03-19
NO943102D0 (no) 1994-08-23
DE69331051T2 (de) 2002-06-13
DE69331051D1 (de) 2001-12-06
ES2162620T3 (es) 2002-01-01
WO1993016691A1 (en) 1993-09-02
DK0627918T3 (da) 2002-01-14
JP3559280B2 (ja) 2004-08-25
US5731346A (en) 1998-03-24
AU3652993A (en) 1993-09-13
EP0627918B1 (en) 2001-10-31
EP0627918A1 (en) 1994-12-14
US5747533A (en) 1998-05-05
NO943102L (no) 1994-10-21

Similar Documents

Publication Publication Date Title
SE9200541D0 (sv) New usee of omega-3-fatty acids
Evans Alcoholic cardiomyopathy
Stephen et al. Scurvy identified in the emergency department: a case report
Master et al. Factors in the onset of coronary occlusion and coronary insufficiency: effort, occupation, trauma, and emotion
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita&#39; antitrombotica e antiarteriosclerotica
ZA200202990B (en) Water and oil containing emulsion.
Hornstra et al. Blood platelets do not provide endoperoxides for vascular prostacyclin production
Brown et al. Dietary protein intake and the glomerular adaptations to partial nephrectomy in dogs
HUP9801593A2 (hu) Benazeprilt vagy benazeprilátot és valzartánt tartalmazó kombinált gyógyszerkészítmények és azok alkalmazása
FR2773712B1 (fr) Composition pharmaceutique comprenant au moins un inhibiteur de l&#39;aminopeptidase a
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
Reinhold et al. The acid-base composition of hepatic bile: I
DE3584131D1 (de) Methode zur behandlung der antidiurese.
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
NO975155D0 (no) Anvendelse av forskolin eller ekstakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet
JPS57209218A (en) Antithrombotic
Wilson The role of prostaglandins in gastric mucosal protection.
Al Aboud Medical Eponyms linked to nails
Unsworth HTLV-III infection in spouses of haemophiliacs.
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
WEKY Haemorrhage
KR940011003A (ko) 우르솔린산을 함유하는 혈관형성 억제제 조성물